article Open AccessTop 1% cited

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Cancer Cell · 2005 · Vol. 7(2) · pp. 129–141

Ellen Weisberg✉(Harvard University)Paul W. Manley(Novartis (Switzerland))Werner Breitenstein(Novartis Institutes for BioMedical Research)Josef Brüggen(Novartis (Switzerland))Sandra W. Cowan‐Jacob(Novartis Institutes for BioMedical Research)Arghya Ray(Harvard University)Brian J.P. Huntly(Brigham and Women's Hospital)Doriano Fabbro(Novartis (Switzerland))Gabriele Fendrich(Novartis (Switzerland))Elizabeth Hall–Meyers(Harvard University)Andrew L. Kung(Dana-Farber Cancer Institute)Jürgen Mestan(Novartis Institutes for BioMedical Research)George Q. Daley(Boston Children's Hospital)Linda M. Callahan(Harvard University)Laurie Catley(Harvard University)Cara Cavazza(Harvard University)Mohammed Azam(Boston Children's Hospital)Donna Neuberg(Harvard University)Renee D. Wright(Brigham and Women's Hospital)D. Gary Gilliland(Brigham and Women's Hospital)James D. Griffin(Harvard University)

View via DOI Full-text PDF

Chronic Myeloid Leukemia Treatments Acute Lymphoblastic Leukemia research Chronic Lymphocytic Leukemia ResearchMutantCancer researchMutationChemistryCell biologyBiologyBiochemistryGene

MeSH terms

Imatinib MesylateAnimalsAntineoplastic AgentsBenzamidesBone Marrow CellsCell LineCell SurvivalDose-Response Relationship, DrugHematopoietic Stem CellsModels, BiologicalModels, ChemicalMutationMycoplasmaPhosphorylationPiperazines

Citations

1,480

FWCI

49.59

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)